CHF5993

Phase 2Small molecule

CHF5993 is one of 52 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

AsthmaActive, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Singulair

AstraZeneca

Preclinical

17 4

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 5

Cinqair

Teva

Preclinical

13 6

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 7

Asmanex

Novartis

Preclinical

5 8

Spiriva

Boehringer Ingelheim

Preclinical

8 9

Atrovent

Boehringer Ingelheim

Preclinical

5 10

Arcoxia

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Asthma

NCT07301736

Clinical

Trials by Indication[1]

Asthma2 trials

Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 3·NCT06264674·836 enrolled

A Phase II Multinational, Multicentre, Double-blind, Randomised, Active-controlled, 3-way Cross-over Study to Evaluate the Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a Versus CHF5993 pMDI 100/6/12.5 µg HFA-134a in Subjects With Mild to Moderate Asthma

Recruiting· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 2·NCT07301736·780 enrolled

PMD1 trial

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 1·NCT05830071·95 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 2·NCT03590379·366 enrolled

Exercise1 trial

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 4·NCT05097014·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for CHF5993. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CHF5993 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CHF5993. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chiesi Farmaceutici S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Chiesi Farmaceutici S.p.A.

CHF5993

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Asthma2 trials

PMD1 trial

Chronic Obstructive Pulmonary Disease1 trial

Exercise1 trial

References

Drug Info

Quick Facts

Related News